ong-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
Phase 1
Recruiting
- Conditions
- Solid and Hematological MalignanciesTherapeutic area: Diseases [C] - Neoplasms [C04]
- Registration Number
- CTIS2023-507041-28-00
- Lead Sponsor
- Kite Pharma Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 504
Inclusion Criteria
The subject must have received an infusion of gene-modified cells in a completed Kite-sponsored parent study, has not withdrawn full consent or discontinued the parent study, and must have completed the minimum duration of follow-up assessments in the parent study, as applicable., The subject must understand and voluntarily sign an Informed Consent Form (ICF) or an Informed Assent Form prior to any study-related assessments or procedures being conducted., In the investigator’s judgment, the subject must be willing and able to complete the protocol-required follow-up schedule and comply with the study requirements for participation.
Exclusion Criteria
There are no specific exclusion criteria for this study.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method